Skip to content

Study on the Impact of Short-term ONS on Body Composition and Quality of Life in Patients Undergoing Postoperative Chemotherapy for Gastric Cancer

Study on the Impact of Short-term ONS on Body Composition and Quality of Life in Patients Undergoing Postoperative Chemotherapy for Gastric Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121603
Enrollment
Unknown
Registered
2026-04-01
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric adenocarcinoma

Interventions

Trial group:Dietary guidance +ONS

Sponsors

lu an shi ren min yi yuan: Lu'an People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 70 years old, pathologically diagnosed with gastric adenocarcinoma, and within 1 to 3 months after undergoing D2 radical resection (unifying the surgical approach to reduce confounding factors); 2. The SOX chemotherapy regimen (teggio + oxaliplatin, 21 days as one cycle, unified chemotherapy regimen to control drug effects) is proposed, and it is the first cycle of chemotherapy; 3. Nutritional Risk Screening (NRS 2002) score >=3 points (nutritional risk exists, ensuring the necessity of intervention); 4. Physical Condition Score (ECOG PS) 0-1 point (stable physical condition, able to cooperate with intervention and assessment); 5. Patients and their families have given informed consent and participate voluntarily.

Exclusion criteria

Exclusion criteria: 1. Combined with underlying diseases such as severe liver and kidney dysfunction (Child-Pugh grade C) and heart failure (NYHA grade III-IV); 2. Severe sarcopenia already existed before chemotherapy (skeletal muscle index < 7.0 kg/m^2 in men and < 5.7 kg/m^2 in women); 3. Allergic to the ingredients of oral nutritional supplements (such as whey protein and vitamins); 4. There are conditions such as gastrointestinal obstruction and bleeding that prevent oral intake; 5. The expected survival period is less than 6 months, or there is cognitive impairment that makes it impossible to cooperate with the assessment.

Design outcomes

Primary

MeasureTime frame
Quality of life score;Body composition;

Secondary

MeasureTime frame
Serum albumin;Serum prealbumin;Gastrointestinal reaction;

Countries

China

Contacts

Public ContactXinghao Ma

lu an shi ren min yi yuan: Lu'an People's Hospital

271307026@qq.com+86 564 359 7034

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026